United Services Automobile Association boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 36.4% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 59,636 shares of the medical device company’s stock after acquiring an additional 15,908 shares during the quarter. United Services Automobile Association owned about 0.07% of DexCom worth $5,664,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of DXCM. Waddell & Reed Financial Inc. lifted its holdings in shares of DexCom by 164.8% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock valued at $54,075,000 after buying an additional 354,331 shares during the period. UBS Group AG lifted its holdings in shares of DexCom by 76.3% in the 1st quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock valued at $1,181,000 after buying an additional 6,890 shares during the period. BlackRock Inc. lifted its holdings in shares of DexCom by 5.9% in the 2nd quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock valued at $390,978,000 after buying an additional 228,933 shares during the period. Macquarie Group Ltd. lifted its holdings in shares of DexCom by 14.4% in the 2nd quarter. Macquarie Group Ltd. now owns 236,341 shares of the medical device company’s stock valued at $22,448,000 after buying an additional 29,825 shares during the period. Finally, Federated Investors Inc. PA lifted its holdings in shares of DexCom by 97.1% in the 2nd quarter. Federated Investors Inc. PA now owns 460,209 shares of the medical device company’s stock valued at $43,710,000 after buying an additional 226,740 shares during the period.

In other DexCom news, SVP Jeffrey Moy sold 5,831 shares of the business’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $94.13, for a total transaction of $548,872.03. Following the completion of the sale, the senior vice president now directly owns 68,511 shares in the company, valued at approximately $6,448,940.43. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jacob Steven Leach sold 47,600 shares of the business’s stock in a transaction that occurred on Friday, September 28th. The stock was sold at an average price of $143.95, for a total value of $6,852,020.00. Following the sale, the insider now owns 109,284 shares of the company’s stock, valued at $15,731,431.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 201,104 shares of company stock valued at $26,507,570. 1.80% of the stock is owned by company insiders.

Shares of DexCom stock opened at $127.07 on Friday. The company has a quick ratio of 4.62, a current ratio of 4.89 and a debt-to-equity ratio of 0.69. DexCom, Inc. has a twelve month low of $43.74 and a twelve month high of $148.56. The stock has a market capitalization of $12.64 billion, a P/E ratio of -214.42 and a beta of 0.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. DexCom had a negative return on equity of 7.45% and a negative net margin of 0.65%. The firm had revenue of $242.50 million during the quarter, compared to analyst estimates of $205.81 million. During the same quarter in the previous year, the business earned ($0.16) EPS. DexCom’s revenue for the quarter was up 42.1% compared to the same quarter last year. Analysts forecast that DexCom, Inc. will post -0.47 earnings per share for the current fiscal year.

Several equities analysts have recently issued reports on DXCM shares. Northland Securities raised DexCom from an “under perform” rating to a “market perform” rating in a report on Wednesday, September 12th. Raymond James raised DexCom from a “market perform” rating to an “outperform” rating in a report on Monday, July 2nd. BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 21st. BMO Capital Markets lifted their price target on DexCom to $112.00 and gave the company an “outperform” rating in a research note on Tuesday, July 10th. Finally, Stephens lifted their price target on DexCom from $135.00 to $160.00 and gave the company an “overweight” rating in a research note on Thursday, August 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. DexCom presently has an average rating of “Buy” and a consensus price target of $123.13.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: What does RSI mean?

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.